Caxton Corp Elevation Oncology, Inc. Transaction History

Caxton Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$0.65 - $1.56 $57 - $137	88 Added 0.41%	21,813 $14,000
Q2 2023 Aug 14, 2023	SELL	$1.4 - $5.06 $65,238 - $235,790	-46,599 Reduced 68.2%	21,725 $33,000
Q4 2022 Feb 14, 2023	BUY	$0.89 - $1.19 $24 - $32	27 Added 0.04%	68,324 $64,000
Q3 2022 Nov 14, 2022	BUY	$1.03 - $1.53 $4 - $6	4 Added 0.01%	68,297 $77,000
Q2 2022 Aug 15, 2022	BUY	$1.26 - $3.94 $17 - $55	14 Added 0.02%	68,293 $96,000
Q1 2022 May 16, 2022	BUY	$2.34 - $6.41 $30,373 - $83,201	12,980 Added 23.47%	68,279 $172,000
Q4 2021 Feb 14, 2022	BUY	$4.15 - $8.86 $29,531 - $63,047	7,116 Added 14.77%	55,299 $333,000
Q3 2021 Nov 15, 2021	BUY	$7.66 - $16.11 $65,853 - $138,497	8,597 Added 21.72%	48,183 $375,000
Q2 2021 Aug 16, 2021	BUY	$11.44 - $13.57 $452,863 - $537,182	39,586 New	39,586 $537,000

45.4M

700

27.6K

Ticker ELEV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,300,900
Market Cap $13.5M
Description
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced sol...

Get notified when there are updates to the investment portfolio of Caxton Corp, based on Form 13F filings with the SEC.

Stay updated on Caxton Corp with notifications on news.